Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Comparison of isatuximab-pom-dex vs. elotuzumab-pom-dex in relapsed/refractory myeloma patients in a target trial emulation using real-world data favors Isa-Pd on some long-term outcomes but shows less infection risk with EloPd.”

“Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data”

Authors: Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, Giovanni Tripepi, Massimo Gentile et al.

Myeloma Paper of the Day, March 6th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.